Abnormal myo-inositol and phospholipid metabolism in cultured fibroblasts from patients with ataxia telangiectasia

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1437, Issue 3, 1999, Pages 287-300

  Yorek, Mark A ^a   Dunlap, Joyce A ^a   Manzo Fontes, Arturo ^b   Bianchi, Roberto ^c   Berry, Gerard T ^d   Eichberg, Joseph ^b  

^a Diabetes Endocrinology Researh Ctr   (United States)

^b University of Houston   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ataxia telangiectasia; Human fibroblast; myo Inositol; Phosphatidic acid; Phosphatidylglycerol; Phospholipid metabolism

Indexed keywords

GENE PRODUCT; INOSITOL; PHOSPHATIDIC ACID; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPID; PHOSPHORUS 32; PROTEIN KINASE;

ARTICLE; ATAXIA TELANGIECTASIA; AUTOSOMAL RECESSIVE DISORDER; BIOACCUMULATION; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IONIZING RADIATION; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TURNOVER TIME;

ATAXIA TELANGIECTASIA; CELL DIVISION; CELL LINE; CELLS, CULTURED; CHOLINE; FIBROBLASTS; GLYCEROPHOSPHOLIPIDS; HUMANS; INOSITOL; PHOSPHATIDYLINOSITOLS; PHOSPHORUS RADIOISOTOPES;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0033602443     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-1981(99)00022-0     Document Type: Article

References (54)

1. Harnden D.G. The nature of ataxia telangiectasia: problems and perspectives. Int. J. Radiat. Biol. 66:1994;S13-S19.
2. Lavin M.F., Shiloh Y. The genetic defect in AT. Annu. Rev. Immunol. 15:1997;177-202.
3. Swift M., Morrell D., Massey R.B., Chase C.L. Incidence of cancer in 161 families affected by ataxia telangiectasia. N. Engl. J. Med. 325:1991;1831-1836.
4. Weeks D.E., Patterson M.C., Lange K., Andrais B., Davis R.C., Yoder F., Gatti R.A. Assessment of chronic gamma radiosensitivity as an in vitro assay for heterozygote identification of ataxia telangiectasia. Radiat. Res. 128:1991;90-99.
5. Easton D.F. Cancer risks in AT heterozygotes. Int. J. Radiat. Biol. 66:1994;S177-S182.
6. 2 delay and spontaneous chromosome aberrations in ataxia telangiectasia homozygotes and heterozygotes. Int. J. Radiat. Biol. 66:1994;S157-S163.
7. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1995;1749-1753.
8. Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., Shiloh Y., Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet. 4:1995;2025-2032.
9. Kastan M M. Ataxia telangiectasia: broad implications for a rare disorder. N. Engl. J. Med. 333:1995;662-663.
10. Chen G., Lee E.Y.-H.P. The product of the ATM gene is a 370-kDa nuclear phosphoprotein. J. Biol. Chem. 271:1996;33693-33697.
11. Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y., Tagle D.A. The ataxia telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage. Proc. Natl. Acad. Sci. USA. 94:1997;1840-1845.
12. Barlow C., Brown K.D., Deng C.X., Tagle D.A., Wynshaw-Boris A. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint apoptotic pathways. Nat. Genet. 17:1997;453-456.
13. Beamish H., Lavin M.F. Radiosensitivity in ataxia telangiectasia: anomalies in radiation-induced cell cycle delay. Int. J. Radiat. Biol. 65:1994;175-184.
14. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
15. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell. 71:1992;587-597.
16. Lu X., Lane D.P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell. 75:1993;765-778.
17. Khanna K.K., Lavin M.F. Ionizing radiation and UV induction of p53 by different pathways in ataxia telangiectasia cells. Oncogene. 8:1993;3307-3312.
18. Artuso M., Esteve A., Vuillaume M., Hall J. The role of the ataxia telangiectasia gene in the p53, WAF1/CIP1 (p21) and GADD45-mediated response to DNA damage produced by ionizing radiation. Oncogene. 11:1995;1427-1435.
19. Eyn M.S., Strasfeld L., Allen C. Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia telangiectasia. Int. J. Radiat. Biol. 66:1994;S141-S149.
20. Rice B.D., Youmell M.B. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 56:1996;246-250.
21. Baskaran R., Wood L.D., Whitaker L.L., Canman C.E., Morgan S.E., Xu Y., Barlow C., Baltimore D., Wynshaw-Boris A., Kastan M.B., Wang J.Y.J. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature. 387:1997;516-519.
22. Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., Kufe D., Lavin M.F. Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 387:1997;520-523.
23. Banin S., Moyal L., Taya S.-Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677.
24. Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
25. Price B.D., Youmell M.B. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 56:1996;246-250.
26. Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.A., Abraham R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58:1998;4375-4382.
27. Berry G.T., Prantner J.E., States B., Yandrasitz J.R. The effect of glucose and galactose toxicity on myo-inositol transport and metabolism in human skin fibroblasts in culture. Pediatr. Res. 35:1994;141-147.
28. Yorek M.A., Dunlap J.A., Ginsberg B.H. myo-Inositol uptake by four cultured mammalian cell lines. Arch. Biochem. Biophys. 246:1986;801-807.
29. Lees M.B., Paxman S. Modification of the Lowry procedure for the analysis of proteolipid protein. Anal. Biochem. 47:1972;184-192.
30. Fine J.B., Sprecher H. Unidimensional thin-layer chromatography of phospholipids on boric acid-impregnated plates. J. Lipid Res. 23:1982;660-663.
31. Clarke N.G., Dawson R.M.C. N transacylation. A new method for the quantitative deacylation of phospholipids. Biochem. J. 195:1981;301-306.
32. Berridge M.J., Irvine R.F. Inositol phosphates and cell signaling. Nature. 341:1989;197-205.
33. Burg M.B. Molecular basis of osmotic regulation. Am. J. Physiol. 268:1995;F983-F996.
34. Wiese T.J., Dunlap J.A., Conner C.E., Grzybowski J.A., Lowe W.L. Jr., Yorek M.A. Osmotic regulation of Na-myo-inositol cotransporter mRNA level and activity in endothelial and neural cells. Am. J. Physiol. 270:1996;C990-C997.
35. +-ATPase activity in rats maintained on L-fucose diet: reversal by myo-inositol supplementation. Diabetes. 42:1993;1401-1406.
36. Swift M. Genetic aspects of ataxia telangiectasia. Immunodef. Rev. 2:1990;67-81.
37. Schalch D.S., McFarlane D.E., Barlow M.H. An unusual form of diabetes mellitus in ataxia telangiectasia. N. Engl. J. Med. 282:1970;1396-1402.
38. Blevins L.S. Jr., Gebhart S.S. Insulin-resistant diabetes mellitus in a black woman with ataxia telangiectasia. South. Med. J. 89:1996;619-621.
39. Kofman O., Belmaker R.H. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol. Psychiatry. 34:1993;839-852.
40. Benjamin J., Levine J., Fux M., Aviv A., Levy D., Belmaker R.H. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am. J. Psychiatry. 152:1995;1084-1086.
41. Levine J., Barak Y., Gonzalves M., Szor H., Elizur A., Kofman O., Belmaker R.H. Double-blind, controlled trial of inositol treatment of depression. Am. J. Psychiatry. 152:1995;792-794.
42. Palmer F.B., Cook H.W., Byers D.M. Thapsigargin selectively stimulates synthesis of phosphatidylglycerol in N1E-115 neuroblastoma cells and phosphatidylinositol in C6 glial cells. Biochim. Biophys. Acta. 1215:1994;190-197.
43. Esko J.D., Raetz C.R.H. Mutants of Chinese hamster ovary cells with altered membrane phospholipid composition. J. Biol. Chem. 255:1980;4474-4480.
44. Kondo N., Inoue R., Nishimura S., Kasahara K., Kameyama T., Miwa Y., Lorenzo P.R., Orii T. Defective calcium-dependent signal transduction in T lymphocytes of ataxia telangiectasia. Scand. J. Immunol. 38:1993;45-48.
45. Khanna K.K., Yan J., Watters D., Hobson K., Beamish H., Spring K., Shiloh Y., Gatti R.A., Lavin M.F. Defective signaling through the B cell antigen receptor in Epstein-Barr virus-transformed ataxia telangiectasia cells. J. Biol. Chem. 272:1997;9489-9495.
46. Rotman G., Shiloh Y. Ataxia telangiectasia: is ATM a sensor of oxidative damage and stress? BioEssays. 19:1997;911-917.
47. Jackowski S. Cell cycle regulation of membrane phospholipid composition. J. Biol. Chem. 271:1996;20219-20222.
48. Jackowski S S. Coordination of membrane phospholipid synthesis with the cell cycle. J. Biol. Chem. 269:1994;3858-3867.
49. Xia W., Dowhan W. In vivo evidence for the involvement of anionic phospholipids in initiation of DNA replication in Escherichia coli. Proc. Natl. Acad. Sci. USA. 92:1995;783-787.
50. Dowhan W. Molecular basis for membrane phospholipid diversity: Why are there so many lipids? Annu. Rev. Biochem. 66:1997;199-232.
51. Joseleau-Petit D., Kepes F., Kepes A. Cyclic changes of the rate of phospholipid synthesis during synchronous growth of Escherichia coli. Eur. J. Biochem. 139:1984;605-611.
52. Kaszkin M., Richards J., Kinzel V. Phosphatidic acid formation by phospholipase D is involved in the phorbol 12-myristate 13-acetate-induced G2 delay of A431 cells. Biochem. J. 314:1996;129-138.
53. Murray N.R., Fields A.P. Phosphatidylglycerol is a physiologic activator of nuclear protein kinase C. J. Biol. Chem. 273:1998;11514-11520.
54. II protein kinase C is required for the G2/M phase transition of cell cycle. J. Biol. Chem. 271:1996;15045-15053.